Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC; SUMMIT/CREST Investigators.

Blood. 2005 Dec 1;106(12):3777-84. Epub 2005 Aug 11.

2.

A practical update on the use of bortezomib in the management of multiple myeloma.

San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H.

Oncologist. 2006 Jan;11(1):51-61. Review.

3.

Bortezomib in multiple myeloma.

Mateos MV, San Miguel JF.

Best Pract Res Clin Haematol. 2007 Dec;20(4):701-15. Review.

PMID:
18070714
4.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

5.

Proteasome inhibition for treatment of multiple myeloma: clinical update.

Stadtmauer EA.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S10-5. Review.

PMID:
19795531
6.

Bortezomib in multiple myeloma.

Terpos E, Roussou M, Dimopoulos MA.

Expert Opin Drug Metab Toxicol. 2008 May;4(5):639-54. doi: 10.1517/17425255.4.5.639 . Review.

PMID:
18484921
7.

Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.

Moore H, Romeril K.

Intern Med J. 2011 Apr;41(4):348-50. doi: 10.1111/j.1445-5994.2011.02458.x. Review.

PMID:
21507163
8.

Update on the optimal use of bortezomib in the treatment of multiple myeloma.

Mohan M, Matin A, Davies FE.

Cancer Manag Res. 2017 Mar 2;9:51-63. doi: 10.2147/CMAR.S105163. eCollection 2017. Review.

Supplemental Content

Support Center